An Open Study of the Safety and Pharmacokinetics of GNR-038 in Sequential Dose-increase Cohorts in Healthy Volunteers
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs GNR 038 (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions
- Sponsors GENERIUM Pharmaceuticals
- 15 Sep 2020 Status changed from recruiting to completed.
- 07 Jan 2020 New trial record